Novogene expands its European operations with new genomics facility at the IZB in Munich, Germany
December 12, 2023
Das Life Sciences-Team von Andera Partners investiert international in Biotech- und Medtech-Unternehmen.
Opening of a new Novogene genomics laboratory at the IZB Munich
Martinsried near Munich, December 12, 2023 – The Innovation and Start-up Center for Biotechnology (IZB), one of the leading biotechnology centers in Europe, and home to over 40 biotech start-ups, today announced the opening of a new genomics laboratory by Novogene, a leading global provider of genomics services and solutions. The recently founded subsidiary Novogene GmbH has decided to open its first laboratory in Martinsried. The lab is expected to be fully operational in early 2024. Alongside its established UK lab, this new facility in Germany will build on Novogene’s global localisation strategy, which brings highly optimised processes coupled with expert local staff to provide an industry leading service to the scientific community in Europe.
Tingting Zhou, Vice President of Novogene Europe, said: “We are very excited to join the IZB eco-system. This new lab will not only expand our capacity but also enable us to collaborate more closely with researchers and innovators in biotechnology across Europe.”
Dr. Peter Hanns Zobel, Managing Director of IZB, added: “We are delighted Novogene has chosen our dynamic biotech center for their new genomics facility. The inclusion of Novogene on our campus represents an important new collaboration. Their expertise in genomic services will greatly complement the diverse and cutting-edge scientific activities at IZB and enhance the research and innovation potential of our network of biotech companies and academic institutions.”
Novogene is a leading global provider of next-generation sequencing (NGS) services and solutions. It makes significant contributions to improving human heath, agriculture, and environmental protection through continuously advancing genomics. With leading-edge NGS platforms, well developed bioinformatics pipelines and an exceptional team of highly skilled professionals, Novogene has become a trusted NGS provider across Europe. For more information visit: www.novogene.com
About the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich
The Fördergesellschaft IZB mbH, founded in 1995, operates the Innovation and Start-up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan and has developed into a leading biotechnology center. 40 biotech companies and five life science firms with over 700 employees are currently based on 26,000 m2. Here, work is being done on developing drugs for the most serious diseases, such as cancer, Alzheimer’s, and various autoimmune diseases. A key criterion for the success of the IZBs is the physical proximity to cutting-edge research on the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt chemistry college, the two kindergartens Bio Kids and Bio Kids2 as well as the two restaurants SEVEN AND MORE, and THE BOWL Food Lounge are also location factors that are highly valued by the founders of the company. Successful companies that emerged from the IZB include Corimmun (today Janssen-Cilag), Crlelux (today Wuxxi AppTec), Exosome Diagnostics (bought by Bio-Techn), ibidi, Immunic Therapeutics, Medigene, Micromet (today Amgen), MorphoSys, Octopharma or Rigontec (now MSD) as well as SIRION Biotech (today Perkin Elmer). More information at www.izb-online.com.
IZB Press Contact:
Marion Köhler, Head of Public Relations
Innovation and Start-up Center Biotechnology (IZB)
Am Klopferspitz 19, D-82152 Planegg-Martinsried,
Phone: +49 (0)89/55 279 48-17, Email: ed.enilno-bzi@relheok